Serum insulin-like growth factor binding protein 2 is associated with hepatic steatosis in adults with metabolic dysfunction-associated steatotic liver disease.

ABSTRACT:

Objective

To evaluate the association between serum insulin-like growth factor binding protein 2 (IGFBP2) and the degree of hepatic steatosis in patients with MASLD.

Methods

A total of 347 patients with metabolic dysfunction-associated steatotic liver disease (MASLD) were enrolled, adhering to the inclusion criteria. The controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) were measured by FibroScan, while serum IGFBP2 levels were quantified by ELISA. Hepatic IGFBP2 mRNA expression data were obtained from the Gene Expression Omnibus database (GEO database). Levels of serum IGFBP2 and hepatic IGFBP2 mRNA between healthy controls and MASLD patients were separately compared. Correlation analyses were performed to evaluate the relationships between CAP an

SUBMITTER: Wang Z 

PROVIDER: S-EPMC12278360 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature